Search results
Results from the WOW.Com Content Network
A.P. Pharma's lead product candidate, APF530, is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV). One of the most debilitating ...
A.P. Pharma, Inc. Announces Planned Name Change to "Heron Therapeutics, Inc." and Application to List on NASDAQ Capital Market REDWOOD CITY, Calif.--(BUSINESS WIRE) ...
A.P. Pharma Resubmits New Drug Application for APF530, a Product Candidate for the Prevention of Chemotherapy-Induced Nausea and Vomiting REDWOOD CITY, Calif.--(BUSINESS WIRE)-- A.P. Pharma, Inc ...
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois.It is ranked sixth on the list of largest biomedical companies by revenue.In 2023, the company's seat in Forbes Global 2000 was 74, [2] and rank 89 on the 2024 list. [3]
The following table lists the largest biotechnology and pharmaceutical companies ranked by market capitalization in billion US dollars. The change column indicates the company's relative position in this list compared to their relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
By 2005, Dr. Patrick Soon-Shiong merged American BioScience and the publicly-held APP, naming it Abraxis BioScience. [8] Under this new name, seventy-four trials were undertaken to test Abraxane against various cancer targets. [8] The drug, which was approved by the FDA in 2005, was the subject of a litigation (Elan Pharma v.
A.P. Pharma Makes Key Appointments in Preparation of Potential FDA Approval of Lead Product Candidate, APF530 - Joel Schaedler named as Vice President of Market Access - - Daniel Martin named Vice ...
In July 2019, the FDA-approved Aptar Pharma's Unidose Powder System as the first intranasally-delivered, needle-free rescue treatment for severe hypoglycemia. [13] In 2020, during the COVID-19 pandemic, Aptar invested in new tools to accelerate its molding equipment and assembly machines for pumps, but it still wasn't enough to keep up with demand.